GSK Stops Camlipixant Program in Refractory Chronic Cough After Phase 3 Data
MT Newswires Live
Jul 17
GSK (GSK) will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials, the company said Friday.
In the phase 3 program, camlipixant 50 mg twice daily significantly reduced 24-hour cough frequency versus placebo in CALM-1 but failed to reach statistical significance in CALM-2, while the 25 mg dose failed to meet the primary endpoint in both trials.
GSK said limited efficacy prompted its decision to discontinue camlipixant's development in refractory chronic cough, while the phase 2b BALANCE trial in irritable bowel syndrome will continue.
GSK shares were down over 3% in premarket activity Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.